Bolt Biotherapeutics will present Phase 1 clinical trial data for BDC-3042, a dectin-2 agonist antibody targeting tumor-associated macrophages (TAMs), at the 2025 AACR Annual Meeting. The company will also share preclinical data on two Boltbody™ ISAC programs targeting CEA and PD-L1. The Phase 1 trial focuses on BDC-3042’s efficacy in patients with advanced solid tumors, including non-small cell lung cancersmall cell lung cancer (NSCLC).
This data release is important because it offers insights into a novel approach to cancer immunotherapy. Activating TAMs, which are typically immunosuppressive in the tumor microenvironment, represents a new strategy with the potential to significantly improve treatment outcomes in difficult-to-treat cancers like NSCLC. The presentation of preclinical data for the CEA and PD-L1 targeting ISACs further underscores Bolt’s commitment to developing innovative cancer therapies and expands the potential applications of their platform technology.
The Phase 1 trial for BDC-3042 is a dose-escalation study evaluating the safety and preliminary efficacy of the drug. The preclinical data for the CEA and PD-L1 targeting Boltbody™ ISACs will likely showcase the mechanism of action and anti-tumor activity in preclinical models. These presentations provide crucial early-stage evidence of Bolt’s platform’s potential to create effective immunotherapies.
The data presented at AACR will be a significant catalyst for Bolt Biotherapeutics. Positive clinical and preclinical results could attract further investment, partnerships, and accelerate the development of these promising therapies. It will also offer a crucial benchmark against other approaches in the immuno-oncology field, potentially positioning Bolt as a leader in TAM-targeted therapies.
Jon Napitupulu is Director of Media Relations at The Clinical Trial Vanguard. Jon, a computer data scientist, focuses on the latest clinical trial industry news and trends.
